Susanne Jung

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: August 18, 2026

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Journal: The Lancet. Haematology

Published: September 18, 2025

Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.

Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.

Journal: Frontiers in immunology

Published: May 07, 2025

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Journal: ImmunoTargets and therapy

Published: April 17, 2025

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

Journal: Journal for immunotherapy of cancer

Published: March 20, 2025

Bispecific antibodies in prostate cancer therapy

Bispecific antibodies in prostate cancer therapy

Journal: Urologie (Heidelberg, Germany)

Published: March 10, 2025

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Journal: Frontiers in immunology

Published: August 18, 2024

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Journal: Frontiers in oncology

Published: July 02, 2024

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.

Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.

Journal: Cancers

Published: June 05, 2024

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Journal: Frontiers in oncology

Published: May 31, 2024

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Journal: Frontiers in oncology

Published: January 08, 2024

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).

Journal: Frontiers in oncology

Published: December 07, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026